free web stats

Xolair Might Cause Blood Clots As Well As Brain, Heart, And Lung Problems / Side Effects, Including Strokes And Deaths

 

In a rush? You can use our Quick Contact Form to tell us the basic information about your case.

 
Xolair (omalizumab), which is an injectable drug for certain patients with asthma or chronic hives, has been available in the US since June 2003.

The drug companies responsible for Xolair are Genentech (manufacturer) and Novartis Pharmaceuticals (marketing partner).

In September 2014 the FDA issued an update about its safety review of Xolair and therein pointed out these possible Xolair side effects:

Heart Attacks
Pulmonary Hypertension
Blood Clots
Pulmonary Embolism (PE)
Deep Vein Thrombosis (DVT)
Brain Blood Vessel Problems

In addition, as set forth in a 2012 medical journal article, two University of Florida researchers who analyzed an FDA voluntary adverse drug event reporting database found that there was a strong “safety signal” for Xolair as regards cardiovascular death and stroke events.

Back in July 2009 the FDA issued its “Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair)” to inform doctors and patients that the agency had started reviewing interim safety findings from a study of Xolair which suggested that this medication may be associated with increased risks for ischemic heart disease, arrhythmias, cardiomyopathy, cardiac failure, pulmonary hypertension, cerebrovascular disorders, and thromboembolic and thrombophlebitic events.

We are investigating possible Xolair lawsuits involving side effects resulting in patient injury or death such as the following cases:

Xolair – Heart Attack – 40 yr old woman

Xolair – Chronic Pulmonary Embolism – 48 yr old man

Xolair – Brain Blood Vessel Problems – 13 yr old girl

___________________________________________________________________________

Free Xolair Case Evaluation

We encourage you to submit a Drug Injury Law Case Reviewit is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.

____________________________________________________________________

FDA Drug Safety Communication: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events

This update is in follow-up to the Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair) issued on July 16, 2009.

[9-26-2014]

Safety Announcement

A U.S. Food and Drug Administration (FDA) review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug Xolair (omalizumab) than in those who were not treated with Xolair. As a result, we have added information about these potential risks to the drug label. Patients taking Xolair should continue to take the medication as prescribed and discuss any questions or concerns with their health care professionals….

___________________________________________________________

Xolair Is Associated With Higher Than Expected Reporting Of Arterial Thrombotic Events Such As Strokes And Cardiovascular Deaths

While European Drug Regulators Have Been Concerned About This Aspect Of Xolair Safety, FDA Has No Warning About Arteriothrombotic Risks Of Xolair

SUMMARY: In this post we consider a medical journal article which suggests that Xolair is associated with an increased risk of arterial thrombotic events, predominantly cardiovascular deaths and strokes.

The subject article is “Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting”, initially published online by the Journal of Asthma and Allergy back in May 2012.

According to the authors, their study is the first pharmacovigilance analysis to detect from a spontaneous event reporting database such as the FDA AERS a strong safety signal for Xolair as regards cardiovascular death and stroke events.

Numerous times throughout their article the authors acknowledge the limitations of their research methods and state that epidemiological studies are necessary to further explore the apparent association of Xolair with cardiovascular deaths, strokes, and other arterial thrombotic adverse events.

[Read this article in full at original source]

__________________________________________________________

Earlier articles by attorney Tom Lamb on the Side Effects Blog:

__________________________________________________________

Xolair Drug Injury or Death Case Evaluation >>

__________________________________________________________

All content by attorney Tom Lamb

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, NC 28403
(800) 426-9535
ThomasJLamb@DrugInjuryLaw.com
Disclaimer and Copyright